BRM:FRA
Bristol-Myers Squibb Co
51,01 €
arrow_upward
+1,07%(+0,54) 1D
14 ოქტ, 10:57:11 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BRM...
Open
50,51 €
High
51,01 €
Low
50,51 €
Mkt. cap
115,76 მლრ.
Avg. vol.
224,00
Volume
40,00
52-wk high
60,64 €
52-wk low
36,65 €
No. of employees
32 ათ.
Open
50,51 €
High
51,01 €
Low
50,51 €
Mkt. cap
115,76 მლრ.
Avg. vol.
224,00
Volume
40,00
52-wk high
60,64 €
52-wk low
36,65 €
No. of employees
32 ათ.
News stories
From web sources and news partners
BioSpace
·
2 საათის წინ
J&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutback
The Motley Fool
·
14 საათის წინ
Bristol Myers Squibb vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?
Trefis
·
16 საათის წინ
What Does Bristol-Myers Squibb Offer That Pfizer Does Not?
MarketBeat
·
21 საათის წინ
Bristol Myers Squibb (NYSE:BMY) Stock Price Target Cut by Wells Fargo & Company
Profile
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States.
The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000. Wikipedia
About Bristol-Myers Squibb Co
CEOქრის ბერნერი
Employees32,5 ათ.
Founded1887
Headquartersნიუ-იორკი, ნიუ-იორკის შტატი, ამერიკის შეერთებული შტატები
SectorPharmaceutical industry
Websitebms.com